logo-loader
AIM:ETX

e-Therapeutics PLC

Receive alerts
Market:
AIM
Market Cap:
£38.75 m
Price
12.02 GBX
Change
-0.06%
52 weeks high
23.00
52 weeks low
1.25

Our Business Model

Maximising return on investment and value to our shareholders

How we create value

We bring to the biotechnology and pharmaceutical industries the power to discover new and better drugs in a more effective way

  • Public and proprietary big data
  • Expertise in network biology
  • Advanced analytical tools and techniques

Click here for more information on our strategy.

Overview

We utilise our biological expertise and our powerful computer-based platform to create and analyse network models of disease processes, identifying patterns of proteins that could be disrupted to treat disease. This is our Network-Driven Drug Discovery ("NDD") approach.

Click here for more information on what we do.

Our Assets

We have validated our approach in diverse areas of biology, from oncology to immunology to neurodegeneration

NDD-derived assets: current self-funded programmes

We are currently focusing our internal resources on two self-funded NDD-derived immuno-oncology programmes. Click on the projects below to read more.

Tryptophan catabolism

Tryptophan plays an important role in regulating immune tolerance, as demonstrated in the maintenance of the immune privilege of the placenta. The catabolism of tryptophan has been more recently revealed in tumours where it is purported to contribute towards immune evasion, with cancer cells suppressing T cell responses via both depletion of tryptophan and accumulation of its metabolite kynurenine. Project aim: To identify novel modulators of tryptophan catabolism with a distinct mechanism and superior pharmacological characteristics.

Immune checkpoint modulation

Immune checkpoints are part of the normal physiological 'braking system' of the immune response. Immune cell populations, such as T cells, carry receptors that transmit suppressive messages to the interior if they meet the appropriate external signal. In cancer, these signals can be generated inappropriately by tumour cells, thereby contributing to immune evasion by tumours. Project aim: To identify mechanistically novel small molecule modulators of immune checkpoint signalling that can be used in combination with existing treatments to improve patient responses; and in situations where patients do not respond to standard care.

Click here for more information on our assets.

United Kingdom.

OUR BOARD

Ali Mortazavi

Ali has extensive experience in the biotechnology sector and financial markets. Recent roles include CEO of Silence Therapeutics plc from 2012-2018 as well as a founder shareholder of Evolution Group, a U.K. based Investment Bank, from 2001-2008. Ali is an experienced investor in small companies and has held numerous declarable stakes in listed and private biotechnology and technology companies.

Professor Trevor Jones CBE

Trevor has over 40 years’ distinguished experience in the pharmaceutical and biotechnology industries as well as in academia. He is currently a Non-Executive Director of the life sciences investment company Arix Bioscience plc. He is also Visiting Professor at King’s College, London and holds honorary degrees and Gold Medals from seven universities. Previously, Trevor held significant roles in industry including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Trevor has also held a number of advisory and regulatory roles including Director General of the Association of the British Pharmaceutical Industry ("ABPI"), Board member of the European Federation of Pharmaceutical Industry Associations ("EFPIA") and the International Federation of Pharmaceutical Manufacturers Associations ("IFPMA"), a member of the UK Government regulatory agency, The Medicines Commission, a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals, an adviser to the Cabinet Office on the Human Genome Project, a member of the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry ("PICTF") and Chair of the Government Advisory Group on Genetics Research. He joined the e-therapeutics Board in October 2015 and chairs the Remuneration Committee.

Michael Bretherton

Michael was appointed to the Board of e-therapeutics plc as a Non-Executive Director in February 2020. He is also Chairman of the Audit Committee and a member of the Remuneration Committee. Michael is currently Chief Executive Officer of Sarossa Plc. In addition, he is Non-Executive Chairman of Adams Plc and Hardy Oil & Gas Plc and he is also a non-executive director of Blake Holdings Limited and ORA Limited. Michael has been a director of a number of other AIM quoted companies during the last ten years, including DeepMatter Group Plc, Tissue Regenix Group Plc, Nanoco Group Plc and Ceres Power Holdings Plc. He has a degree in Economics from Leeds University and is a member of the Institute of Chartered Accountants in England and Wales. His early career included working as an accountant and manager with PriceWaterhouse for 7 years in London and Abu Dhabi.

Oxford Office and Registered Office
e-therapeutics plc
17 Blenheim Office Park
Long Hanborough
Oxfordshire
OX29 8LN

Newcastle Office
e-therapeutics plc
City Quadrant 
11 Waterloo Square 
Newcastle Upon Tyne 
NE1 4DP

Email

General Enquiries
[email protected]

Phone & Fax

Tel: +44 (0) 1993 880000
Fax: +44 (0) 1993 880207

Nominated advisor and broker
Numis Securities Limited
10 Paternoster Row
London
EC4M 7LT
020 7260 1000
www.numis.com

  • Richard Griffiths and controlled undertakings – 94,800,167 (29.40%)
  • Ali Mortazavi - 49,000,000 (15.20%)
  • Lombard Odier Asset Management – 21,394,589 (6.64%)
  • David Norwood - 17,000,000 (5.27%)
  • Octopus Investments Ltd – 11,097,658 (3.44%)

Last updated: 06 March 2020

Nominated advisor and broker
Numis Securities Limited
10 Paternoster Row
London
EC4M 7LT
020 7260 1000
www.numis.com

Auditors
Deloitte LLP
PO Box 3043
Abbots House
Abbey Street
Reading
RG1 3BD
www.deloitte.co.uk

Solicitors
Womble Bond Dickinson (UK) LLP
St. Ann’s Wharf
112 Quayside
Newcastle upon Tyne
NE1 3DX
Tel: +44 (0) 844 984 1500
Fax: +44 (0) 844 984 1501
www.bonddickinson.com

Registrars
Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen
West Midlands
B63 3DA
Tel: +44 (0) 121 585 1131
Fax: +44 (0) 121 585 1132

Bankers
Bank of Scotland
PO Box No 10
38 St. Andrews Square
Edinburgh
EH2 2AD
Tel: +44 (0) 131 465 3900
www.bankofscotland.co.uk